Pathological trajectory in the Ts65Dn model of Down syndrome

Savannah Tallino; Wendy Winslow; Ramon Velazquez

doi:10.18632/aging.204497

Pathological trajectory in the Ts65Dn model of Down syndrome

Savannah Tallino, Wendy Winslow, Ramon Velazquez

Research output: Contribution to journal › Editorial › peer-review

Abstract

As the world’s population ages, dementia from Alzheimer’s disease (AD) is projected to increase astronomically; individuals with Down syndrome (DS) are counted among those virtually guaranteed to develop AD pathology and, if they live long enough, AD dementia [1, 2]. DS is characterized by intellectual disability and for decades featured a high incidence of congenital heart abnormalities leading to early mortality. However, recent medical advances drastically improved the life expectancy in DS; more than a quarter of a million people living with DS in the United States are now projected to age long enough to develop AD [2].

Original language	English (US)
Pages (from-to)	295-297
Number of pages	3
Journal	Aging
Volume	15
Issue number	2
DOIs	https://doi.org/10.18632/aging.204497
State	Published - 2023
Externally published	Yes

Keywords

Down syndrome
Ts65Dn
amyloid-beta
cholinergic

ASJC Scopus subject areas

Aging
Cell Biology

Access to Document

10.18632/aging.204497

Cite this

@article{5845f8e0490242c28ba0e3faf85659aa,

title = "Pathological trajectory in the Ts65Dn model of Down syndrome",

abstract = "As the world{\textquoteright}s population ages, dementia from Alzheimer{\textquoteright}s disease (AD) is projected to increase astronomically; individuals with Down syndrome (DS) are counted among those virtually guaranteed to develop AD pathology and, if they live long enough, AD dementia [1, 2]. DS is characterized by intellectual disability and for decades featured a high incidence of congenital heart abnormalities leading to early mortality. However, recent medical advances drastically improved the life expectancy in DS; more than a quarter of a million people living with DS in the United States are now projected to age long enough to develop AD [2].",

keywords = "Down syndrome, Ts65Dn, amyloid-beta, cholinergic",

author = "Savannah Tallino and Wendy Winslow and Ramon Velazquez",

note = "Publisher Copyright: {\textcopyright} 2023 Tallino et al. This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",

year = "2023",

doi = "10.18632/aging.204497",

language = "English (US)",

volume = "15",

pages = "295--297",

journal = "Aging",

issn = "1945-4589",

publisher = "US Administration on Aging",

number = "2",

}

TY - JOUR

T1 - Pathological trajectory in the Ts65Dn model of Down syndrome

AU - Tallino, Savannah

AU - Winslow, Wendy

AU - Velazquez, Ramon

N1 - Publisher Copyright: © 2023 Tallino et al. This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PY - 2023

Y1 - 2023

N2 - As the world’s population ages, dementia from Alzheimer’s disease (AD) is projected to increase astronomically; individuals with Down syndrome (DS) are counted among those virtually guaranteed to develop AD pathology and, if they live long enough, AD dementia [1, 2]. DS is characterized by intellectual disability and for decades featured a high incidence of congenital heart abnormalities leading to early mortality. However, recent medical advances drastically improved the life expectancy in DS; more than a quarter of a million people living with DS in the United States are now projected to age long enough to develop AD [2].

AB - As the world’s population ages, dementia from Alzheimer’s disease (AD) is projected to increase astronomically; individuals with Down syndrome (DS) are counted among those virtually guaranteed to develop AD pathology and, if they live long enough, AD dementia [1, 2]. DS is characterized by intellectual disability and for decades featured a high incidence of congenital heart abnormalities leading to early mortality. However, recent medical advances drastically improved the life expectancy in DS; more than a quarter of a million people living with DS in the United States are now projected to age long enough to develop AD [2].

KW - Down syndrome

KW - Ts65Dn

KW - amyloid-beta

KW - cholinergic

UR - http://www.scopus.com/inward/record.url?scp=85147536418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147536418&partnerID=8YFLogxK

U2 - 10.18632/aging.204497

DO - 10.18632/aging.204497

M3 - Editorial

C2 - 36707069

AN - SCOPUS:85147536418

SN - 1945-4589

VL - 15

SP - 295

EP - 297

JO - Aging

JF - Aging

IS - 2

ER -

Pathological trajectory in the Ts65Dn model of Down syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this